Subtopic Deep Dive
CAR-T Therapy for Solid Tumors
Research Guide
What is CAR-T Therapy for Solid Tumors?
CAR-T therapy for solid tumors applies chimeric antigen receptor-engineered T cells to treat non-hematologic malignancies facing barriers like poor tumor infiltration and immunosuppressive microenvironments.
Unlike liquid tumors where CD19 CAR-T succeeds, solid tumors challenge CAR-T with antigen heterogeneity and stromal inhibition. Engineering advances target antigens like mesothelin and GD2 for improved persistence. Over 50 clinical trials explore these adaptations as of 2023.
Why It Matters
CAR-T success in leukemia (Maude et al., 2014; 5256 citations) contrasts with solid tumor failures due to limited access, as detailed in Sterner and Sterner (2021; 2498 citations). Beatty et al. (2013; 843 citations) showed mesothelin CAR-T mRNA-engineered T cells induce antitumor activity in solid malignancies like mesothelioma and pancreatic cancer. Extending efficacy to solid tumors, comprising 90% of cancers, could transform oncology outcomes.
Key Research Challenges
Tumor Microenvironment Inhibition
Solid tumor stroma and immunosuppressive cells block CAR-T infiltration and function. Sterner and Sterner (2021) highlight cytokine exhaustion and TGF-β suppression as key limiters. Louis et al. (2011; 1143 citations) observed poor persistence in neuroblastoma despite GD2 targeting.
Antigen Heterogeneity Escape
Tumor cells downregulate or mutate target antigens, enabling immune evasion. Beatty et al. (2013) noted off-target risks with mesothelin expression in normal tissues. Sterner and Sterner (2021) report antigen loss in 30-50% of solid tumor relapses post-CAR-T.
Limited T Cell Infiltration
Dense extracellular matrix and vascular barriers prevent CAR-T access to tumor cores. Waldman et al. (2020; 3941 citations) describe TME hypoxia impairing trafficking. Louis et al. (2011) found CAR-T confined to tumor periphery in neuroblastoma patients.
Essential Papers
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · 2014 · New England Journal of Medicine · 5.3K citations
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom ...
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo · 2020 · Nature reviews. Immunology · 3.9K citations
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee, Bianca Santomasso, Frederick L. Locke et al. · 2018 · Biology of Blood and Marrow Transplantation · 3.1K citations
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang, Zemin Zhang · 2020 · Cellular and Molecular Immunology · 2.6K citations
Abstract Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoin...
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner · 2021 · Blood Cancer Journal · 2.5K citations
Abstract Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certai...
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei et al. · 2017 · Nature Reviews Clinical Oncology · 2.3K citations
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi, Robert Yuan, Edgar G. Engleman · 2020 · Annual Review of Pathology Mechanisms of Disease · 2.1K citations
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) fo...
Reading Guide
Foundational Papers
Start with Maude et al. (2014; 5256 citations) for CAR-T baseline in leukemia, then Beatty et al. (2013; 843 citations) for first solid tumor application via mesothelin CAR mRNA-T cells, and Louis et al. (2011; 1143 citations) for GD2 CAR persistence lessons in neuroblastoma.
Recent Advances
Study Sterner and Sterner (2021; 2498 citations) for current limitations and strategies, Waldman et al. (2020; 3941 citations) for TME immunotherapy context, and Zhang and Zhang (2020; 2640 citations) for tumor-infiltrating cell advances.
Core Methods
Core techniques: second-generation CARs with CD28/4-1BB costimulation (Maude et al., 2014), mRNA transient expression to reduce off-target toxicity (Beatty et al., 2013), and cytokine-armored CARs countering TME suppression (Sterner and Sterner, 2021).
How PapersFlow Helps You Research CAR-T Therapy for Solid Tumors
Discover & Search
Research Agent uses searchPapers('CAR-T solid tumors mesothelin') to retrieve Beatty et al. (2013), then citationGraph reveals 843 citing works on infiltration strategies, and findSimilarPapers uncovers Sterner and Sterner (2021) for limitation analyses.
Analyze & Verify
Analysis Agent applies readPaperContent on Beatty et al. (2013) to extract mesothelin CAR efficacy data in solid tumors, verifyResponse with CoVe cross-checks claims against Maude et al. (2014), and runPythonAnalysis plots survival curves from trial stats with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in antigen targeting via contradiction flagging between Louis et al. (2011) and Sterner (2021), while Writing Agent uses latexEditText for manuscript revisions, latexSyncCitations for 250+ reference integration, and latexCompile for camera-ready figures; exportMermaid visualizes CAR-T persistence pathways.
Use Cases
"Analyze survival data from mesothelin CAR-T trials in pancreatic cancer"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Beatty 2013 data) → matplotlib plot with GRADE verification.
"Draft review section on solid tumor CAR-T challenges with citations"
Synthesis Agent → gap detection (Sterner 2021 vs Louis 2011) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF with integrated bibliography.
"Find code for CAR-T tumor infiltration simulations"
Research Agent → paperExtractUrls (Waldman 2020) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebook on TME modeling.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'CAR-T solid tumors', structures report on challenges with DeepScan's 7-step CoVe checkpoints verifying Sterner (2021) claims. Theorizer generates hypotheses on dual-antigen CARs from Beatty (2013) and Louis (2011) patterns, exporting Mermaid diagrams of engineered persistence pathways.
Frequently Asked Questions
What defines CAR-T therapy for solid tumors?
CAR-T for solid tumors engineers T cells against antigens like GD2 or mesothelin to overcome TME barriers, unlike CD19 success in leukemia (Maude et al., 2014).
What are main methods in solid tumor CAR-T?
Methods include mRNA-engineered CARs for transient expression (Beatty et al., 2013) and armored CARs resisting TGF-β (Sterner and Sterner, 2021).
What are key papers on solid tumor CAR-T?
Beatty et al. (2013; 843 citations) on mesothelin CARs, Louis et al. (2011; 1143 citations) on GD2 in neuroblastoma, Sterner and Sterner (2021; 2498 citations) on limitations.
What open problems exist in solid tumor CAR-T?
Unresolved issues include infiltration (Waldman et al., 2020), antigen escape (Sterner and Sterner, 2021), and toxicity management beyond CRS grading (Lee et al., 2018).
Research CAR-T cell therapy research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CAR-T Therapy for Solid Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the CAR-T cell therapy research Research Guide